Under construction – not a live service
Sign in
Taking people in ItalyNo phase

Study on Blood Pressure Variability and Frailty in the Older People

Key facts

Where
Milan, ItalySee the site

Where in Italy

  • Istituto Auxologico Italiano IRCCSMilan, ItalyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Istituto Auxologico Italiano
Trial code
NCT06868069
Record updated
30 March 2026
Original description
Observational prospective single-center, non-profit study. Primary objective of the study: To determine if the hypotensive phenotype, defined as one episode of daytime systolic blood pressure (SBP) <90 mmHg (or two episodes of daytime SBP <90 mmHg, if mean 24 h SBP is <125 mmHg) detected at Ambulatory Blood Pressure Monitoring (ABPM) is associated with adverse events at follow up (death, hospitalization, falls, emergency room admission for uncontrolled hypertension, major cardiovascular events)Read full original descriptionShow less

Study on Blood Pressure Variability and Frailty in the Older People: the HypoPHrail Study

Observational prospective single-center, non-profit study. Primary objective of the study: To determine if the hypotensive phenotype, defined as one episode of daytime systolic blood pressure (SBP) <90 mmHg (or two episodes of daytime SBP <90 mmHg, if mean 24 h SBP is <125 mmHg) detected at Ambulatory Blood Pressure Monitoring (ABPM) is associated with adverse events at follow up (death, hospitalization, falls, emergency room admission for uncontrolled hypertension, major cardiovascular events)

Inclusion: Age ≥ 75 years; Diagnosis of hypertension according to the criteria of the European Society of Cardiology guidelines [Williams 2018]; Consent of the patient (or legal representative) to participate in the study.

Exclusion: Refusal of the patient or his/her legal representative; Life expectancy of less than 6 months.

ClinicalTrials.gov NCT06868069